We thank Cecile Montgiraud, Juliette Gimenez, Magali Jaillard and Bertrand Bonnaud for their contribution to the initial development and optimization of the HERV-V2 protocol. We also wish to thank Hader Haidous for his guidance on ethical considerations.

1. Surgery
Once removed by the surgeon, keep the prostate on ice until taken in charge of by a pathologist.
2. Handling of Prostate Tissues
<ol>
	<li>To respect the delay of perioperative ischemia, transfer radical prostatectomy specimens on ice to the laboratory by dedicated staff within 30 min after surgical ablation. The delay of freezing should be less than 20-30 min (Figure 3A).</li>
	<li>Weigh and stain the prostate according to the usual protocol (e.g. green on the right side, black on the left side, see Figures 3B and 3C).</li>
	<li>Perform a large transverse section of the gland on the posterior side (Figure 3D). Orient the prostate and put it on the anterior side. Perform a large transverse section of the gland on the posterior side with a sterile surgical knife.</li>
	<li>Dissect pieces of tissue on the transition zone, on the left and right peripheral zones, leaving the margins intact (Figure 3E).</li>
	<li>Put the cores of tissue in an Eppendorf tube, snap freeze and store in liquid nitrogen (Figure 3F). If you are not making biobank proceed directly with step 2.7.</li>
	<li>Perform prostate banking only if the total length of cancer on biopsies is superior to 10 mm. Use a suture thread to close the prostate and to prevent gland distortion and minimal disruption of the surgical margin (Figure 3G). Then fix the radical prostatectomy specimen with formalin and embed in paraffin according to the usual procedure for histological analysis.</li>
	<li>Mount frozen tissue cores vertically upon a small mound of OCT and make sections in a cryostat. Take a first single 5 &#181;m frozen section and stain it with blue toluidine.</li>
	<li>Perform a quick histological examination to analyze the nature of the tissue (i.e. benign or malignant). For tumoral tissue, estimate the quantity of tumoral cells and select only cores with more than 80% of tumoral cells.</li>
	<li>Following this, perform a new single 5 &#181;m frozen section and stain it with hematoxylin, eosin and Safran. Then, cut 15 sections x 30 &#181;m and place it in a RNAse free Eppendorf tube.</li>
	<li>Take a last 5 &#181;m frozen section for hematoxylin, eosin and Safran and stain it to control the quantity of tumoral cells at the end of the procedure.</li>
	<li>Put the Eppendorf tube in dry ice and send the sample to the molecular biology laboratory.</li>
</ol>
3. RNA Extraction, Purification, and Quality Control
<ol>
	<li>Homogenization. Perform homogenization in the presence of 1 ml&#160;of Trizol/100 mg tissue until the tissue is completely dissolved in solution. Add Trizol solution gradually and proceed with care on ice using a hand-held grinder. Once homogenized, aliquot the solution to Eppendorf tubes and leave in Trizol at room temp for five minutes.</li>
	<li>Phase separation. Add 300 &#181;l&#160;chloroform (or 150 &#181;l&#160;BCP/1.5 ml&#160;Trizol). Vortex 15 sec&#160;then leave at room temp for 2-3 min. Centrifuge at 12,000 x g for 15 min at 2-8 &#176;C.</li>
	<li>RNA precipitation. Transfer carefully the top aqueous phase to a new tube. Add 750 &#181;l&#160;isopropanol. Incubate at RT for 10 min (agitate by reversal). Incubate 2 hr at -19 &#176;C/-31 &#176;C. Centrifuge samples at 12,000 x g for 30 min at 2-8 &#176;C.</li>
	<li>RNA wash and suspension. Following centrifugation, remove the supernatant. Wash RNA pellet with 1 ml&#160;80% EtOH (gently reverse the tubes). Centrifuge samples at 7,500 x g for 10 min at 2-8 &#176;C. Remove supernatant using P1000 and P10. Allow remaining EtOH to air dry for 2-3 min. Add 100 &#181;l&#160;RNase-free water, transfer tubes to 70 &#176;C heat block and let sit for 2-3 min to dissolve the pellet. Then put on ice. Store at -19 &#176;C/-31 &#176;C for short term storage and -80 &#176;C for long term storage.</li>
	<li>RNA purification. Purify RNA using the RNeasy Mini kit (Qiagen). Briefly, start by adding 350 &#181;l buffer RLT to the 100 &#181;l&#160;RNA sample and mix well, then follow the Qiagen procedure. Finally, take a 3 &#181;l&#160;(out of 50 &#181;l) aliquot of the purified product for quality controls (step 3.6). Store RNA at -19 &#176;C/-31 &#176;C for a short term period or at -80 &#176;C for a long term storage.</li>
	<li>RNA QC (Figure 4A). Check the quality of RNA and the RNA integrity using a Bioanalyzer (Agilent) and a Nanodrop (Thermo), according to the manufacturer instructions. The RNA Integrity Number (RIN) is used to assess the RNA quality. In particular, succeed in the detection of 18S and 28S peaks is strongly recommended to use the samples in further steps.</li>
</ol>
4. WT-ovation RNA Amplification
Recommendations to perform the amplification steps using the WT-Ovation amplification kit in optimal conditions:
<ul>
	<li>Run no fewer than eight amplification samples at a time to ensure pipetting precision. Then, account for 1 waste volume when preparing master mixes that require a splitting of the kit into 3 batches of 8 reactions.</li>
	<li>Always keep thawed reagents and reaction tubes on ice unless otherwise instructed.</li>
	<li>Use only a fresh 80% ethanol solution for purification.</li>
	<li>Do not stop at any stage of the protocol.</li>
</ul>

<ol>
	<li>Dilute total RNA to get a concentration of 25 ng/&#181;l. Process 2 &#181;l of the diluted sample.</li>
	<li>Prepare the Poly-A RNA spike-in control solution by a serial dilution of the Poly-A RNA Stock with Poly-A Control Dilution Buffer (Affymetrix), to achieve a 1:25,000 dilution.
		 Step 1: First Strand cDNA Synthesis from 4.3 - 4.8. The reagents mentioned are referred by the supplier as follows: A1 (First Strand Primer Mix), A2 (First Strand Buffer Mix), A3 (First Strand Enzyme Mix). 
	</li>
	<li>Thaw A1 and A2 at room temperature. Mix by using a vortex-mixer for 2 sec&#160;and spin for 2 sec. Then, quickly place on ice. Place A3 on ice.</li>
	<li>Put 2 &#181;l of total RNA (50 ng) in a 0.2 ml PCR tube and add 2 &#181;l of A1 (final volume: 4 &#181;l). Cap and spin the tube for 2 sec.</li>
	<li>Incubate at 65 &#176;C for 5 min&#160;then place the tube on ice.</li>
	<li>Prepare the First Strand cDNA Master Mix as follows (given for a single reaction). Mix by pipetting and spin down the Master Mix briefly. Immediately, place on ice.
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>First Strand Buffer Mix (A2)</td>
					<td>5 &#181;l</td>
				</tr>
				<tr>
					<td>Poly-A RNA Control (1:25,000)</td>
					<td>0.5 &#181;l</td>
				</tr>
				<tr>
					<td>First Strand Enzyme Mix (A3)</td>
					<td>0.5 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add 6 &#181;l of the Master Mix to the RNA/Primer-containing tube. Mix by flicking the tube, spin for 2 sec&#160;and quickly place on ice (final volume: 10 &#181;l).</li>
	<li>Incubate at 4 &#176;C for 1 min, then 25 &#176;C for 10 min, then 42 &#176;C for 10 min&#160;and then 70 &#176;C for 15 min. Keep cool at 4 &#176;C. Remove the reaction tube from thermal cycler, spin briefly and keep on ice. Continue immediately with the Second Strand cDNA Synthesis step. Step 2: Second Strand cDNA Synthesis from 4.8 - 4.12. The reagents mentioned are referred by the supplier as follows: B1 (Second Strand Buffer Mix) and B2 (Second Strand Enzyme Mix). 
	</li>
	<li>Spin down B2 and B3 for 2 sec&#160;and quickly place on ice. Thaw B1 at room temperature. Mix by using a vortex-mixer for 2 sec, spin for 2 sec&#160;and quickly place on ice.</li>
	<li>Prepare a Second Strand Master Mix as follows (given for a single reaction). Mix by pipetting and spin down the Master Mix briefly. Immediately, place on ice.
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>Second Strand Buffer Mix (B1)</td>
					<td>9.75 &#181;l</td>
				</tr>
				<tr>
					<td>Second Strand Enzyme Mix (B2)</td>
					<td>0.25 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add 10 &#181;l of the Master Mix to each First Strand Reaction tube. Mix by pipetting 3x, spin for 2 sec&#160;and place on ice (final volume: 20 &#181;l).</li>
	<li>Incubate at 4 &#176;C for 1 min, then 25 &#176;C for 10 min, then 50 &#176;C for 30 min, and then 70 &#176;C for 5 min. Keep cool at 4 &#176;C. Remove the reaction tube from thermal cycler, spin briefly and keep on ice. Continue immediately with the Post-Second Strand Enhancement step. Step 3: Post-Second Strand Enhancement from 4.13 - 4.15. The reagents mentioned are referred by the supplier as follows: B1 (Second Strand Buffer Mix), B3 (Reaction Enhancement Enzyme Mix). 
	</li>
	<li>Prepare a Master Mix by combining B1 and B3 Mix as follows (given for a single reaction). Mix by pipetting and spin down the Master Mix briefly. Immediately, place on ice.
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>Second Strand Buffer Mix (B1)</td>
					<td>1.9 &#181;l</td>
				</tr>
				<tr>
					<td>Reaction Enhancement Enzyme Mix (B3)</td>
					<td>0.1 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add 2 &#181;l of the Master Mix to each Second Strand Reaction tube. Mix by pipetting 3x, spin for 2 sec&#160;and place on ice (final volume: 22 &#181;l).</li>
	<li>Incubate at 4 &#176;C for 1 min, then 37 &#176;C for 15 min, and then 80 &#176;C for 20 min. Keep cool at 4 &#176;C. Remove the reaction tube from thermal cycler, spin briefly and place on ice. Continue immediately with the SPIA Amplification step. Step 4: Single strand cDNA (sscDNA) synthesis by SPIA procedure from 4.16 - 4.19. The reagents mentioned are referred by the supplier as follows: C1 (SPIA Primer Mix), C2 (SPIA Buffer Mix), C3 (SPIA Enzyme Mix). 
	</li>
	<li>Thaw the C1 and C2 at room temperature. Mix by using a vortex-mixer, spin for 2 sec&#160;and quickly place on ice. Thaw C3 on ice. Mix the content by gently inverting 5x. Make sure not to introduce air-bubbles. Then, spin for 2 sec&#160;and place on ice.</li>
	<li>Prepare a SPIA-Master Mix, accounting for a 0.5 waste volume, as follows. Mix by pipetting and spin down the Master Mix briefly. Immediately, place on ice.
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>SPIA-Buffer Mix (C2)</td>
					<td>5 &#181;l</td>
				</tr>
				<tr>
					<td>SPIA-Primer Mix (C1)</td>
					<td>5 &#181;l</td>
				</tr>
				<tr>
					<td>SPIA-Enzyme Mix (C3)</td>
					<td>10 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add 20 &#181;l of the SPIA Master Mix to the Enhanced Second Strand Reaction tube. Mix by pipetting 6-8x, spin and quickly place on ice (final volume: 42 &#181;l).</li>
	<li>Incubate at 4 &#176;C for 1 min, then 47 &#176;C for 60 min&#160;and then 95 &#176;C for 5 min. Keep cool at 4 &#176;C. Remove the tube from thermal cycler, spin briefly and place on ice.</li>
</ol>
5. sscDNA Purification and Quality Control
<ol>
	<li>sscDNA purification. Purify sscDNA using the QIAquik PCR purification kit (Qiagen). Briefly, start by adding 200 &#181;l buffer PB to the 42 &#181;l&#160;of amplified cDNA product, mix and load on the column. Then follow the Qiagen procedure. Finally, take a 3 &#181;l&#160;(out of 30 &#181;l) aliquot of the sscDNA purified product for quality controls (step 5.2).</li>
	<li>sscDNA yield and size distribution verification (Figure 4B). Check sscDNA yield and size distribution using a Bioanalyzer and a Nanodrop, according to the manufacturer instructions. The size of distribution of amplified cDNA should be typically comprised between 100 and 1,500 bases long with a peak around 600 bases.</li>
</ol>
6. sscDNA Fragmentation
<ol>
	<li>Prepare 2 &#181;g of cDNA in 30 &#181;l, adjusting the volume with Nuclease-free water.</li>
	<li>Prepare 1x One-Phor-All Buffer PLUS (OPA), starting from a 10x OPA buffer PLUS solution.</li>
	<li>Prepare 0.2 U/&#181;l DNase I (5-fold dilution of 1 U/&#181;l DNase I).</li>
	<li>Prepare a Fragmentation Master Mix as follows (given for a single reaction):
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>10X One-Phor-All Buffer PLUS</td>
					<td>3.6 &#181;l</td>
				</tr>
				<tr>
					<td>DNase I (0.2 U/&#181;l)</td>
					<td>3 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add 6.6 &#181;l of Fragmentation Mix to the 30 &#181;l of sscDNA.</li>
	<li>Spin and incubate at 37 &#176;C for 10 min, then inactivate the DNase I at 95 &#176;C for 10 min&#160;and keep on ice. Aliquot 1 &#181;l of the fragmented cDNA for Agilent based-size distribution verification.</li>
	<li>sscDNA size distribution verification (Figure 4C). Check sscDNA size distribution using a Bioanalyzer (Agilent). The size distribution of fragmented cDNA should be typically comprised between 35 and 200 bases.</li>
</ol>
7. Labeling of Fragmented sscDNA
<ol>
	<li>Dilute the DLR-1a 7.5 mM to 5 mM in DEPC-water.</li>
	<li>Prepare a labeling Master Mix as follows (given for a single reaction):
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>5x TdT Reaction Buffer</td>
					<td>14 &#181;l</td>
				</tr>
				<tr>
					<td>CoCl2 (25 mM)</td>
					<td>14 &#181;l</td>
				</tr>
				<tr>
					<td>DLR-1a (5 mM)</td>
					<td>1 &#181;l</td>
				</tr>
				<tr>
					<td>Terminal transferase (400 U/&#181;l)</td>
					<td>4.4 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add 33.4 &#181;l of the labeling mix to each fragmented cDNA sample.</li>
	<li>Mix by flicking the tube, spin briefly and incubate at 37 &#176;C for 60 min, then keep on ice.</li>
</ol>
8. Hybridization to the HERV Chip Microarray
<ol>
	<li>Prewet the HERV GeneChip with 200 &#181;l of PreHybridization Mix (Affymetrix) and incubate at 50 &#176;C, 60 rpm, for 10 min.</li>
	<li>Prepare the Hybridization mix as follows (given for a single reaction):
		<table border="1">
			<tbody>
				<tr>
					<th>Reagent</th>
					<th>Volume</th>
				</tr>
				<tr>
					<td>Control Oligo B2 (3nM)</td>
					<td>3.3 &#181;l</td>
				</tr>
				<tr>
					<td>20x Eukaryotic Hybridization Control</td>
					<td>10 &#181;l</td>
				</tr>
				<tr>
					<td>2x Hybridization Mix</td>
					<td>100 &#181;l</td>
				</tr>
				<tr>
					<td>99.9% DMSO</td>
					<td>17.7 &#181;l</td>
				</tr>
			</tbody>
		</table>
	</li>
	<li>Add the 131 &#181;l of Hybridization Mix to the 69 &#181;l of fragmented and labeled cDNA at room temperature to make a final volume of 200 &#181;l.</li>
	<li>Mix and denature for 2 min&#160;at 95 &#176;C, then incubate at 50 &#176;C for 5 min&#160;and centrifuge at maximum speed for 5 min.</li>
	<li>Empty the prewetted HERV GeneChip and load the 200 &#181;l target preparation. Apply tough-spots on the two septa.</li>
	<li>Hybridize at 50 &#176;C, 60 rpm, for 18 hr.</li>
	<li>After 18 hr, empty the HERV GeneChip and store the collected hybridization solution at 4 &#176;C. Fill the probe array with 250 &#181;l Wash Buffer A. If the chips are not immediately run onto the fluidics, stored at 4 &#176;C.</li>
</ol>
9. Washing and Staining
<ol>
	<li>Run the Fluidics from the GCOS menu bar. In the Fluidics dialog box, select the station of interest (1 - 4), then select Shutdown_450 for all modules, then run. Immerse the 3 Fluidics aspiration lines into Milli-Q water. Follow the LCD screen instructions.</li>
	<li>Apply the Prime_450 program to all modules. Place the tubing for Wash Buffer A in a bottle containing 400 ml Wash Buffer A, and the one for Wash Buffer B in a bottle containing 200 ml Wash Buffer B. Then again, follow the LCD screen instructions.</li>
	<li>Lift up the needles and place 600 &#181;l stain cocktail 1 (SAPE Solution Mix) and 600 &#181;l stain cocktail 2 (Antibody Solution Mix)-containing microcentrifuge tubes at positions # 1 and # 2, and 800 &#181;l array holding buffer solution at position # 3.</li>
	<li>Assign the right chip to each module, select the FS450-004 protocol and run each module, following instructions on screen.</li>
</ol>
10. Scanning
<ol>
	<li>Warm up the GS3000 scanner. It is ready to scan when the light turns green.</li>
	<li>Apply tough-spots onto the septa to avoid leaking then load the chip into the autoloader or alternatively directly into the scanner. Start scanning.</li>
	<li>After scanning the chip, .cel files are generated. Check the image and align the grid to the spot to identify the probe cells (Figures 4D-F).</li>
</ol>
11. Data Analysis
<ol>
	<li>Quality control. Refer to the standard Affymetrix controls to verify that the HERV-V2 chips meet the QC criteria. For this purpose the following representations can be used: the log intensity value distribution (density plots and box plots), the median absolute deviation (MAD) versus the intensity median (MAD-Med) plots, the background plots, the normalized unscaled standard error (NUSE) plots and the relative log expression (RLE) plots.</li>
	<li>Normalization. In addition, the dataset should be explored to highlight unexpected batch effects and to correct them before statistical analysis. The data preprocessing thus includes a background correction (e.g. based on the tryptophan probe baseline signal), followed by RMA normalization and summarization15.</li>
	<li>Data mining and search for differential expressed genes. Normalize the chips and apply a hierarchical clustering approach to explore the dataset (Figure 6A). Then, perform a search for differentially expressed genes (DEG) by using a classical significant analysis of microarray (SAM) procedure16 followed by a false discovery rate (FDR) correction17. Note that these steps are fully integrated in some software analysis suites like Partek GS but can alternatively be performed using the R statistical software18 with packages from the Bioconductor project19. After the statistical analysis, filter the dataset to exclude the probesets for which expression values are less than 26.</li>
	<li>Visualization and interpretation. Interpret the results from the HERV-V2 microarray in a dedicated interface using annotation databases.</li>
</ol>

This work was supported by bioM&#233;rieux SA, the Hospices Civils de Lyon and the French public agency OSEO (Advanced Diagnostics for New Therapeutic Approaches, a French government-funded program dedicated to personalized medicine). PP, VC, GO, NM, and FM are employees of bioM&#233;rieux SA. PP, NM and FM have submitted patent applications covering the findings of this paper.

Over the last 10 years, most of the attempts for HERV expression measurement have used RT-PCR techniques either to focus on a specific locus20-24 or based on the relative conservation of the pol genes to evaluate general trends within HERV genera25,26. Additionally, PCR amplifications using highly degenerated primers coupled with low density microarrays intended to detect and quantify the expression of HERV families27,28. In order to trace the expression of individual locus within a family, approaches based on the PCR amplification of conserved regions combined with subsequent cloning and sequencing enabled transcriptionally active distinct elements of the HML-229,30 or HERV-E4.131 families to be identified. Also ending by cloning and sequencing steps, the genome repeat expression monitoring technique aiming to identify promoters among repeats identified active HML-2 specific human solitary LTRs32,33. We successively developed two generations of high-density microarrays dedicated to the analysis of the HERV transcriptome, introducing methodologies suitable for repeated element probe design in order to minimize cross reactions between paralogous elements within a family34,35. The HERV-V2 chip which targets 2,690 distinct proviruses and 2,883 solo LTRs of the HERV-W, HERV-H, HERV-E 4.1, HERV-FRD, HERV-K HML-2 and HERV-K HML-5 families, unveiled the expression of 1,718 HERV loci (Figures 7A and B) in a wide range of tissues35, illustrated in this paper by the identification of putative prostate cancer biomarkers. In addition, the use of multiple probesets on a given locus is informative about its transcriptional regulation. First, a U3 negative signal in conjunction with a U5 positive one classifies the LTR as a promoter, and conversely U3 positive and U5 negative signals may reflect a polyadenylation role. We thus identified 326 promoter LTRs in a broad range of tissues 35 and, based on this U3-U5 dichotomous information provided by the array, we proposed and experimentally confirmed for some selected cases that such autonomous transcription was controlled by a methylation dependent epigenetic process34 (Figure 8). Second, the detection of signals from e.g. LTR, gag and env independent probesets or issued from probes targeting specific splice junction is informative about the proviral splicing strategy, as illustrated by the ERVWE1/Syncytin1 expression profile in placenta or in tumoral testis34. This indicates that the process of HERV specific probe selection is robust enough to support the identification of tissue-associated splicing strategy, as efficiently as for conventional genes36 (Figure 8).
This method is the first attempt to identify individually HERV locus expression using a custom high density microarray based on Affymetrix technology. The clearly identified advantages of the microarray format to decipher HERV transcriptome consisting of (i) the coordinated exploration of several HERV families and (ii) the simultaneous and independent analysis of the different regions for each locus, e.g. U3 and U5 domains for solo and proviral LTRs, gag or env regions and possible spliced junctions associated with proviral structures, without any a priori on the functionality of the HERV element. Prospects rely upon an improvement of annotations in the microarray-associated biocomputing tools. This should allow one to convert chip signals into biological hypotheses such as whether evidenced active HERVs drive lncRNA transcription or modulate more or less proximal coding gene expression. Indeed, such assumption is supported by recent studies that identified prostate cancer-associated ncRNA transcripts containing components of viral ORFs from the HERV-K endogenous retrovirus family or portions of a viral LTR promoter region37, as well as two gene fusion events namely HERV-K22q11-ETV1 and HERV-K17-ETV38,39. Taken together, this whole transcriptome approach combined with LTR function and splicing strategy identifications may help to decipher the marker versus the trigger components of HERV expression in chronic40,41 and infectious diseases42,43.

Human endogenous retroviruses (also called HERVs) are spread throughout our genome. They originate from ancestral and independent infections within the germ line, followed by copy-paste propagation processes and leading to multicopy families. Today, they are no more infectious but they occupy 8% of the human genome; as a point of comparison, exons span 2% of the human genome. Data from the ENCODE project published in 2012 showed that different RNA types cover about 62% of the genome, including one third in intergenic regions. Moreover, it appears that the amount of transcriptional regulatory motifs is at least 4.5x higher than the one corresponding to protein-coding exons. HERVs long terminal repeats (LTR) represent a broad range of potential transcriptional regulatory elements, as it is their usual function in infectious retroviruses. Historically, apart from a few loci expressed in the placenta or testis, it was commonly believed that HERV are silent due to epigenetic regulation. Therefore, we have designed a high-density microarray, in Affymetrix format, aiming to optimally characterize individual HERV loci expression, in order to better understand whether they are active, if they drive lncRNA transcription or modulate coding gene expression. This tool dubbed HERV-V2 GeneChip integrates 23,583 HERV probesets and can discriminate 5,573 distinct HERV elements composed of solo LTRs as well as complete and partial proviruses (Figure 2).
Diagnosis, Assessment, and Plan:
Diagnosis of prostate cancer is based on dosage of the prostate specific antigen (PSA) biomarker in clinical laboratory, a digital rectal examination to evaluate morphological alteration of the prostate and finally prostate biopsies observed by the pathologist. The lack of sufficient specificity and sensitivity among conventional cancer biomarkers, such as PSA for prostate cancer, has been widely recognized after several decades of clinical implications1. Initially, PSA was proposed for the diagnosis and treatment of adenocarcinoma of the prostate11. It was latter proposed for cancer screening and monitoring the development of the disease12. However, there remains a question which is regularly asked: &#8216;how to use PSA&#39;. (i) A gray zone corresponding to a concentration in serum of 2.5-10 ng/ml does not allow a clear difference to be made between cancer and noncancer2; (ii) two large cohort studies enrolling hundreds of thousands of people in Europe and USA failed to come to a clear conclusion about the usefulness of screening in terms of disease specific mortality13,14; (iii) analysis of post-operative PSA kinetic parameters such as PSA clearance, PSA velocity and doubling time, although simple in theory, can pose considerable challenges in practical application3,4. We may expect that in the coming years, biomarker applications will support a clinical choice between watchful waiting and more or less aggressive treatments depending on tumor phenotype. Concerning the diagnosis rendered by the pathologist, a first limiting factor comes from a 20% false negative diagnosis within prostate biopsies (many cancers are missed by sampling). A second concern deals with the need for an additional biopsy procedure following a negative one, which may present adverse effects.
Radical prostatectomy is currently one of the standard treatments for prostate cancer. It is proposed in healthy patients, aging from 45-65 years, especially in the case of aggressive patterns (Gleason 7 to 10), multifocal tumor or palpable tumor. It is now done in our department using robotic assisted surgery. Because of the growing evidence that molecular markers will have paramount importance in the coming years, we decided to propose to all our patients the possibility of participating in a program for prostate tissue banking. More precisely, the expanding molecular research programs on prostate cancer have resulted in an increasing requirement for access to high quality fresh tumor tissues from prostatectomy specimens. This research, in particular the genomic approaches, required large samples of high DNA/RNA quality. Tumoral and adjacent &#8216;non tumoral&#39; tissues from the same patient are needed. Recommendations for handling and processing radical prostatectomies are designed to preserve pathological features that determine stage and margin status and thereby potential further treatment and prognosis. Any fresh tissue sampling method, therefore, should not compromise subsequent pathological assessments in order to be acceptable to the diagnosis. Macroscopic dissection of the prostate is difficult and great attention needs to be paid to margin tissues and capsular invasion: any dissection for prostate banking should be always conducted by a trained uropathologist according to an agreed protocol. The ethics committee of the medical faculty and the state medical board agreed to these investigations and informed consent was obtained for all patients included in the prostate tissues banking.

<table border="0" cellpadding="0" cellspacing="0" width="717">
	<colgroup>
		<col />
		<col />
		<col />
		<col />
	</colgroup>
	<tbody>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">Trizol</td>
			<td style="width:92px;">Invitrogen</td>
			<td style="width:137px;">15596-026</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">RNA poly-A control stock</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">900433</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">DNAse 1</td>
			<td style="width:92px;">Promega</td>
			<td style="width:137px;">M6101</td>
			<td style="width:295px;">1,000 U (1 U/&#181;l)</td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:195px;">Terminal transferase</td>
			<td style="width:92px;">Roche</td>
			<td style="width:137px;">3333574001</td>
			<td style="width:295px;">400 U. Including enzyme and coenzyme (CoCl2).</td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">DLR-1a</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">900542</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="85">
			<td height="85" style="height:85px;width:195px;">Hybridization internal controls B2 and 20x Eukaryotic Hybridization Control</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">900454</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="64">
			<td height="64" style="height:64px;width:195px;">GeneChip Hybridization, Wash and staining</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">900720</td>
			<td style="width:295px;">Including PreHybridization Mix and 2x Hybridization Mix for 30 reactions</td>
		</tr>
		<tr height="106">
			<td height="106" style="height:106px;width:195px;">10x One-Phor-All Buffer PLUS</td>
			<td style="width:92px;"></td>
			<td style="width:137px;"></td>
			<td style="width:295px;">Composition in DEPC-treated water: 100 mM Tris-acetate pH 7.5; 100 mM magnesium acetate; 500 mM potassium acetate.</td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">RNeasy Mini kit</td>
			<td style="width:92px;">Qiagen</td>
			<td style="width:137px;">74104</td>
			<td style="width:295px;">RNA cleanup protocol</td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:195px;">WT-Ovation RNA amplification system</td>
			<td style="width:92px;">Nugen</td>
			<td style="width:137px;">2210-24</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">QIAquik PCR purification kit</td>
			<td style="width:92px;">Qiagen</td>
			<td style="width:137px;">28104</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:195px;">EQUIPMENT</td>
			<td style="width:92px;"></td>
			<td style="width:137px;"></td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">Material Name</td>
			<td style="width:92px;">Company</td>
			<td style="width:137px;">Catalogue Number</td>
			<td style="width:295px;">Comments</td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:195px;">Nanodrop 1000</td>
			<td style="width:92px;">Thermo Scientific</td>
			<td style="width:137px;"></td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="22">
			<td height="22" style="height:22px;width:195px;">GeneChip Scanner 3000 7G</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">GS30007G</td>
			<td style="width:295px;">Optional: autoloader</td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:195px;">GeneChip Fluidics Station 450</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">FS450</td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="43">
			<td height="43" style="height:43px;width:195px;">GeneChip Hybridization 640 Oven</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;">640</td>
			<td style="width:295px;">Includes 4 GeneChip Probe array carriers</td>
		</tr>
		<tr height="127">
			<td height="127" style="height:127px;width:195px;">Workstation loaded with GeneChip Operating Software (GCOS) including the GeneChip Scanner 3000 High-Resolution Scanning Patch</td>
			<td style="width:92px;"></td>
			<td style="width:137px;"></td>
			<td style="width:295px;"></td>
		</tr>
		<tr height="232">
			<td height="232" style="height:232px;width:195px;">HERV-V2 chip</td>
			<td style="width:92px;">Affymetrix</td>
			<td style="width:137px;"></td>
			<td style="width:295px;">Custom array. 
			For microarray availability (for research use only), please contact: 
			Fran&#231;ois Mallet 
			Laboratoire Commun de Recherche Hospices Civils de Lyon-bioM&#233;rieux 
			Medical Diagnostic Discovery Department 
			Centre Hospitalier Lyon Sud, B&#226;timent 3F 
			69495, Pierre B&#233;nite cedex France 
			Phone: 33 (0)4 72 67 87 85 
			Email: francois.mallet@biomerieux.com</td>
		</tr>
		<tr height="717">
			<td></td>
			<td></td>
			<td></td>
			<td>HERV-V2 conception 
			Dedicated database and annotations 
			 
			The construction of a dedicated database, grouping genomic HERV sequences belonging to 6 HERV families, has been achieved by the following procedure: (i) the most complete and representative sequence of each HERV family was selected from the literature and defined as a prototype sequence (Figure 2). (ii) The 6 prototypes were functionally annotated with reference to their LTR (U3/R/U5) and internal parts (gag/pol/env). (iii) RepeatMasker 44 was then applied using these functional sequences as input libraries. A genome-wide search of all related sequences was performed over the human genome on the basis of a minimum 80% homology (NCBI 36/hg18). (iv) Finally, the functional sequences retrieved by this process were assembled into distinct loci on the basis of their genomic location and eventually implemented in a dedicated HERV database. This database, called HERV-gDB3, contains 10,035 individual HERV loci35. 
			 
			Locus-specific probes design 
			Starting from HERV-gDB3, overlapping tracks of 25-mer candidate probes were firstly generated. Each candidate probe was then aligned against the human genome using KASH 45 in order to assess the cross-hybridization potentialities. This latter estimation was performed by a model developed specifically for this purpose and referred to as EDA+. Briefly, the principle of EDA+ is to take into account the instability brought by mismatches and gaps in a 25-mer target/probe hybridization complex. Candidate probes exhibiting low cross-hybridization risks (i.e. a low number of non-specific genomic targets) are selected and lastly assembled into probesets. 
			 
			Custom HERV GeneChip microarray 
			The custom HERV GeneChip integrates 23,583 HERV probesets and can discriminate 5,573 distinct HERV elements, composed of solo LTRs, complete and partial proviruses (Figure 2). The standard Affymetrix control probes for unbiased amplification and hybridization were also included in the microarray.</td>
		</tr>
	</tbody>
</table>

microarray-based identification of individual herv loci expression: application to biomarker discovery in prostate cancer

The prostate-specific antigen (PSA) is the main diagnostic biomarker for prostate cancer in clinical use, but it lacks specificity and sensitivity, particularly in low dosage values1&#8203;&#8203;. &#8216;How to use PSA&#39; remains a current issue, either for diagnosis as a gray zone corresponding to a concentration in serum of 2.5-10 ng/ml which does not allow a clear differentiation to be made between cancer and noncancer2 or for patient follow-up as analysis of post-operative PSA kinetic parameters can pose considerable challenges for their practical application3,4. Alternatively, noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease, e.g. PCA3 in prostate cancer5,6 and to reveal uncharacterized aspects of tumor biology. Moreover, data from the ENCODE project published in 2012 showed that different RNA types cover about 62% of the genome. It also appears that the amount of transcriptional regulatory motifs is at least 4.5x higher than the one corresponding to protein-coding exons. Thus, long terminal repeats (LTRs) of human endogenous retroviruses (HERVs) constitute a wide range of putative/candidate transcriptional regulatory sequences, as it is their primary function in infectious retroviruses. HERVs, which are spread throughout the human genome, originate from ancestral and independent infections within the germ line, followed by copy-paste propagation processes and leading to multicopy families occupying 8% of the human genome (note that exons span 2% of our genome). Some HERV loci still express proteins that have been associated with several pathologies including cancer7-10. We have designed a high-density microarray, in Affymetrix format, aiming to optimally characterize individual HERV loci expression, in order to better understand whether they can be active, if they drive ncRNA transcription or modulate coding gene expression. This tool has been applied in the prostate cancer field (Figure 1).

The value of transcriptomic studies lies primarily in the quality of the starting biological material. If the RNA extraction is performed in optimal conditions, the RNA Integrity Number (RIN) is typically 7 or greater (Figure 4A). The need to hybridize 2 &#181;g of cDNA on the Affymetrix HERV-V2 chip implies the use of an amplification process. A successful amplification step leads to a bell-shaped distribution (Figure 4B). Then, DNAse1 fragmentation is performed in order to homogenize the cDNA size distribution around 100 nucleotides before hybridization (Figure 4C). After hybridization and scanning (Figure 4D), a visual inspection of the image enables one to check if the grid is well aligned to the spots (Figure 4E) and if hybridization controls are consistent (Figure 4F). This step is also useful in order to exclude microarrays in which air-bubbles or errors occurred during the experiment.
Once the chips have passed QC (Figure 5) and after normalization, the statistical analysis of 5 match-pair tumor and normal prostate RNA samples from the Lyon-Sud Hospital led to the identification of 207 HERV probesets with differential expression values (p.val &#60;0.05) (Figure 6A). To support these records and to gain prostate-specific information, 35 additional match-pair samples (colon, ovary, testis, breast, lung and prostate) were added to the analysis and the SAM-FDR procedure (FDR = 20%) eventually identified 44 prostate specific HERV probesets. Among them, the most relevant 10 HERV structures are described (Figure 6B). Further clinical studies will be required to assess the values of sensitivity and specificity of these candidate biomarkers.
<img alt="Figure 1" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig1.jpg" width="500px" /> 
Figure 1. Scheme of the overall procedure from the clinic (1: prostatectomy by the clinician and the tissue preparation by the pathologist) to the bench (2-6: sample preparation, target preparation, microarray processing) leading to the identification of candidate biomarkers (7: biocomputing analysis of the HERV microarrays). Nucleic acids derived from normal tissue are depicted in orange; nucleic acids derived from tumoral area consist of a mix of normal (orange) and tumor specific (black) nucleic acids. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig1highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 2" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig2.jpg" width="500px" /> 
Figure 2. Conception and content of the HERV-V2 chip: HERV sequences retrieved from the human genome are stored in a database called HERV-gDB3, then the 25-mer candidate probes pass through a dedicated hybridization modeling procedure (EDA+) before being eventually synthesized on the array (the resulting targeted sub-regions are depicted for each family). <a href="https://www.jove.com/files/ftp_upload/50713/50713fig2highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 3" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig3.jpg" width="500px" /> 
Figure 3. Prostate handling by the pathologist. (A) Fresh radical prostatectomy specimen is transferred to the laboratory. (B-C) The prostate is stained (green on the right side, black on the left side). (D) Large transverse section of the gland on the posterior side. (E) Leaving the margins intact, pieces of tissues are dissected from different areas of the prostate gland. (F) Cores of tissue are placed in an Eppendorf tube. (G) Suture thread is used to close the prostate and to prevent gland distortion and minimal disruption of the surgical margin. Then, the radical prostatectomy specimen is ready for fixing in formalin according to the usual procedure for histological analysis. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig3highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 4" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig4.jpg" width="500px" /> 
Figure 4. Quality controls of nucleic acid preparation and hybridization efficiency. (A) RNA integrity, (B) cDNA amplified targets and (C) fragmented targets used in the hybridization stage. These three quality controls were obtained with the Bioanalyzer using RNA nano chips and the Eukaryote Nano Serie II assay. (D) Overall image of the HERV-V2 microarray hybridization area after scanning, (E) enlargement of the upper left corner showing grid alignment controls and (F) enlargement of the center area showing spotting hybridization controls. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig4highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 5" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig5.jpg" width="500px" /> 
Figure 5. Processing of signals. (A) Affymetrix polyA spike-in amplification controls. The polyA controls Dap, Thr, Phe and Lys transcripts from B. subtilis genes are spiked in the RNA sample and serve to assess the overall success of the target preparation steps. Intensity should be detected at decreasing values among these spike-in controls to ensure that there was no bias during the WT-Ovation amplification between highly- and low-expressed genes. (B) Affymetrix spike-in hybridization controls. These targets isolated from E. coli and P1 bacteriophage are spiked before the labeling procedure. Increasing values from BioB, BioC, BioD and Cre indicate the overall success of the hybridization. (C) Intensity distribution of the chip signals after RMA normalization. Most of the probesets exhibit signals with values lower than 26 (background), indicating an overall expression mainly restricted to some specific HERV loci. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig5highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 6" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig6.jpg" width="500px" /> 
Figure 6. Data analysis. (A) Hierarchical clustering analysis of normal and tumoral samples. Partitioning clustering was applied to the normalized expression values using a Euclidean distance function algorithm, grouping probesets into up (red)- and down (blue)-regulation among normal and tumoral samples. (B) Selection of the top 10 HERV structures identified as candidate biomarker of prostate cancer. For each HERV element, the related HERV family, the genomic coordinates (NCBI 36/hg18) and a brief description of the HERV structure are given. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig6highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 7" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig7.jpg" width="500px" /> 
Figure 7. The HERV repertoire. (A) Sequencing of the human genome revealed 25,000 protein-coding genes (exons, 2%) and a huge amount of transposable elements including 200,000 long-terminal repeat (LTR) retrotransposons (HERV, 8%). (B) Extrapolation from HERV-V2 chip content and associated expression data (79 samples originating from 8 normal versus tumoral tissue types) suggest that one third of the HERV repertoire is transcriptionally active. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig7highres.jpg" target="_blank">Click here to view larger image</a>.
<img alt="Figure 8" fo:content-width="6in" src="/files/ftp_upload/50713/50713fig8.jpg" width="500px" /> 
Figure 8. Functional interpretation of signals from the chip. (A) Promoter identification and epigenetic control: U3 negative signal (red probe, 5&#39;LTR) versus R-U5 positive signal (blue probe, 5&#39;LTR) suggest U3-driven transcription, supported by the different CpG methylation (solid black circles) content of U3 in peritumoral normal versus tumoral tissues. (B) Splicing strategy: the putative 3.1 kb envelope encoding mRNA expressed exclusively in the tumor is identified using SD1/SA2 splice junction overlapping probe. *Deduced by the comparison with other non-placental tissues. <a href="https://www.jove.com/files/ftp_upload/50713/50713fig8highres.jpg" target="_blank">Click here to view larger image</a>.

Watch this Scientific Journal Video about Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer at JoVE.com

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Human endogenous retroviruses (HERV), which occupy 8% of the human genome, retain scarce coding capacities but a hundred thousand long terminal repeats (LTRs). A custom Affymetrix microarray was designed to identify individual HERV locus expression and was used on prostate cancer tissues as a proof of concept for future clinical studies.

The prostate-specific antigen (PSA) is the main diagnostic biomarker for prostate cancer in clinical use, but it lacks specificity and sensitivity, ...

microarray-based-identification-individual-herv-loci-expression

Research

JoVE Journal

Medicine

16.5K visualizações.  Joint Unit Hospices de Lyon-bioMérieux.  Retrovírus humanos endógenos (HERV), que ocupam a 8% do genoma humano, manter reduzidas capacidades de codificação, mas a centenas de milhares de repetições terminais longas (LTRs). Um costume microarray Affymetrix foi desenhado para identificar indivíduo expressão HERV lugar e foi usado em tecidos de câncer de próstata como uma prova de conceito para futuros estudos clínicos. 

Vídeo: Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging

Current technologies for tumor imaging, such as ultrasound, MRI, PET and CT, are unable to yield high-resolution images for the assessment of nanoparticle uptake in tumors at the microscopic level1,2,3, highlighting the utility of a suitable xenograft model in which to perform detailed uptake analyses. Here, we use high-resolution intravital imaging to evaluate nanoparticle uptake in human tumor xenografts in a modified, shell-less chicken embryo model. The chicken embryo model is particularly well-suited for these in vivo analyses because it supports the growth of human tumors, is relatively inexpensive and does not require anesthetization or surgery 4,5. Tumor cells form fully vascularized xenografts within 7 days when implanted into the chorioallantoic membrane (CAM) 6. The resulting tumors are visualized by non-invasive real-time, high-resolution imaging that can be maintained for up to 72 hours with little impact on either the host or tumor systems. Nanoparticles with a wide range of sizes and formulations administered distal to the tumor can be visualized and quantified as they flow through the bloodstream, extravasate from leaky tumor vasculature, and accumulate at the tumor site. We describe here the analysis of nanoparticles derived from Cowpea mosaic virus (CPMV) decorated with near-infrared fluorescent dyes and/or polyethylene glycol polymers (PEG) 7, 8, 9,10,11. Upon intravenous administration, these viral nanoparticles are rapidly internalized by endothelial cells, resulting in global labeling of the vasculature both outside and within the tumor7,12. PEGylation of the viral nanoparticles increases their plasma half-life, extends their time in the circulation, and ultimately enhances their accumulation in tumors via the enhanced permeability and retention (EPR) effect 7, 10,11. The rate and extent of accumulation of nanoparticles in a tumor is measured over time using image analysis software. This technique provides a method to both visualize and quantify nanoparticle dynamics in human tumors.

We present a novel approach to quantify nanoparticle localization in the vasculature of human xenografted tumors using dynamic, real-time intravital imaging in an avian embryo model.

Current technologies for tumor imaging, such as ultrasound, MRI, PET and CT, are unable to yield high-resolution images for the assessment of nanoparticle ...

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Currently there is no curative treatment for metastatic clear cell renal cell cancer, the commonest variant of the disease. A key factor in this treatment resistance is thought to be the molecular complexity of the disease 1. Targeted therapy such as the tyrosine kinase inhibitor (TKI)-sunitinib have been utilized, but only 40% of patients will respond, with the overwhelming majority of these patients relapsing within 1 year 2. As such the question of intrinsic and acquired resistance in renal cell cancer patients is highly relevant 3.
In order to study resistance to TKIs, with the ultimate goal of developing effective, personalized treatments, sequential tissue after a specific period of targeted therapy is required, an approach which had proved successful in chronic myeloid leukaemia 4. However the application of such a strategy in renal cell carcinoma is complicated by the high level of both inter- and intratumoral heterogeneity, which is a feature of renal cell carcinoma5,6 as well as other solid tumors 7. Intertumoral heterogeneity due to transcriptomic and genetic differences is well established even in patients with similar presentation, stage and grade of tumor. In addition it is clear that there is great morphological (intratumoral) heterogeneity in RCC, which is likely to represent even greater molecular heterogeneity. Detailed mapping and categorization of RCC tumors by combined morphological analysis and Fuhrman grading allows the selection of representative areas for proteomic analysis.
Protein based analysis of RCC8 is attractive due to its widespread availability in pathology laboratories; however, its application can be problematic due to the limited availability of specific antibodies 9. Due to the dot blot nature of the Reverse Phase Protein Arrays (RPPA), antibody specificity must be pre-validated; as such strict quality control of antibodies used is of paramount importance. Despite this limitation the dot blot format does allow assay miniaturization, allowing for the printing of hundreds of samples onto a single nitrocellulose slide. Printed slides can then be analyzed in a similar fashion to Western analysis with the use of target specific primary antibodies and fluorescently labelled secondary antibodies, allowing for multiplexing. Differential protein expression across all the samples on a slide can then be analyzed simultaneously by comparing the relative level of fluorescence in a more cost-effective and high-throughput manner.

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

RPPA enables the protein expression of hundreds of samples, printed on nitrocellulose slides to be interrogated simultaneously, using fluorescently labelled antibodies. This technique has been applied to study the effect of drug treatment heterogeneity within clear cell renal carcinoma.

Currently there is no curative treatment for metastatic clear cell renal cell cancer, the commonest variant of the disease. A key factor in this treatment ...

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

We have successfully integrated previously established Intracranial window (ICW) technology 1-4 with intravital 2-photon confocal microscopy to develop a novel platform that allows for direct long-term visualization of tissue structure changes intracranially. Imaging at a single cell resolution in a real-time fashion provides supplementary dynamic information beyond that provided by standard end-point histological analysis, which looks solely at 'snap-shot' cross sections of tissue.
Establishing this intravital imaging technique in fluorescent chimeric mice, we are able to image four fluorescent channels simultaneously. By incorporating fluorescently labeled cells, such as GFP+ bone marrow, it is possible to track the fate of these cells studying their long-term migration, integration and differentiation within tissue. Further integration of a secondary reporter cell, such as an mCherry glioma tumor line, allows for characterization of cell:cell interactions. Structural changes in the tissue microenvironment can be highlighted through the addition of intra-vital dyes and antibodies, for example CD31 tagged antibodies and Dextran molecules.
Moreover, we describe the combination of our ICW imaging model with a small animal micro-irradiator that provides stereotactic irradiation, creating a platform through which the dynamic tissue changes that occur following the administration of ionizing irradiation can be assessed.
Current limitations of our model include penetrance of the microscope, which is limited to a depth of up to 900 &mu;m from the sub cortical surface, limiting imaging to the dorsal axis of the brain. The presence of the skull bone makes the ICW a more challenging technical procedure, compared to the more established and utilized chamber models currently used to study mammary tissue and fat pads 5-7. In addition, the ICW provides many challenges when optimizing the imaging.

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

We describe a novel in vivo imaging technique that couples fluorescent chimeric mice with intracranial windows and high-resolution 2-photon microscopy. This imaging platform aids studies of dynamic changes in brain tissue and microvasculature, at a single-cell level, following pathological insults and is adaptable to assess intracranial drug delivery and distribution.

We have successfully integrated previously established Intracranial window (ICW) technology 1-4 with intravital 2-photon confocal microscopy to develop a ...

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Tumor extracellular matrix has abundance of cancer related proteins that can be used as biomarkers for cancer molecular imaging. In this work, we demonstrated effective MR cancer molecular imaging with a small molecular peptide targeted Gd-DOTA monoamide complex as a targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma. We performed the experiment of evaluating the effectiveness of the agent for non-invasive detection of prostate tumor with MRI in a mouse orthotopic PC-3 prostate cancer model. The targeted contrast agent was effective to produce significant tumor contrast enhancement at a low dose of 0.03 mmol Gd/kg. The peptide targeted MRI contrast agent is promising for MR molecular imaging of prostate tumor.

To demonstrate MR cancer molecular imaging with a small peptide targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma in a mouse prostate cancer model.

Tumor extracellular  matrix has abundance of cancer related proteins that can be used as biomarkers  for cancer molecular imaging. In this work,  we ...

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Our laboratory has developed a novel orthotopic implantation model of human prostate cancer (PCa). As PCa death is not due to the primary tumor, but rather the formation of distinct metastasis, the ability to effectively model this progression pre-clinically is of high value. In this model, cells are directly implanted into the ventral lobe of the prostate in Balb/c athymic mice, and allowed to progress for 4-6 weeks. At experiment termination, several distinct endpoints can be measured, such as size and molecular characterization of the primary tumor, the presence and quantification of circulating tumor cells in the blood and bone marrow, and formation of metastasis to the lung. In addition to a variety of endpoints, this model provides a picture of a cells ability to invade and escape the primary organ, enter and survive in the circulatory system, and implant and grow in a secondary site. This model has been used effectively to measure metastatic response to both changes in protein expression as well as to response to small molecule therapeutics, in a short turnaround time.

This orthotopic model of human prostate cancer allows for quantification of tumor size, circulating tumor cells, and formation of distinct metastasis to the lung. As cells must escape the primary organ, enter the blood stream, and implant into a secondary site, this model effectively recapitulates the scenario in humans.

Our laboratory has developed a novel orthotopic implantation model of  human prostate cancer (PCa). As PCa death is not due to the primary tumor, but  ...

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

The cancer stem cell (CSC) model has been considerably revisited over the last two decades. During this time CSCs have been identified and directly isolated from human tissues and serially propagated in immunodeficient mice, typically through antibody labeling of subpopulations of cells and fractionation by flow cytometry. However, the unique clinical features of prostate cancer have considerably limited the study of prostate CSCs from fresh human tumor samples. We recently reported the isolation of prostate CSCs directly from human tissues by virtue of their HLA class I (HLAI)-negative phenotype. Prostate cancer cells are harvested from surgical specimens and mechanically dissociated. A cell suspension is generated and labeled with fluorescently conjugated HLAI and stromal antibodies. Subpopulations of HLAI-negative cells are finally isolated using a flow cytometer. The principal limitation of this protocol is the frequently microscopic and multifocal nature of primary cancer in prostatectomy specimens. Nonetheless, isolated live prostate CSCs are suitable for molecular characterization and functional validation by transplantation in immunodeficient mice.

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.

The cancer stem cell (CSC) model has been considerably revisited over the last two decades. During this time CSCs have been identified and directly ...

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

A critical challenge in prostate cancer (PCa) clinical management is posed by the inadequacy of currently used biomarkers for disease screening, diagnosis, prognosis and treatment. In recent years, microRNAs (miRNAs) have emerged as promising alternate biomarkers for prostate cancer diagnosis and prognosis. However, the development of miRNAs as effective biomarkers for prostate cancer heavily relies on their accurate detection in clinical tissues. miRNA analyses in prostate cancer clinical specimens is often challenging owing to tumor heterogeneity, sampling errors, stromal contamination etc. The goal of this article is to describe a simplified workflow for miRNA analyses in archived FFPE or fresh frozen prostate cancer clinical specimens using a combination of quantitative real-time PCR (RT-PCR) and in situ hybridization (ISH). Within this workflow, we optimize the existing methodologies for miRNA extraction from FFPE and frozen prostate tissues and expression analyses by Taqman-probe based miRNA RT-PCR. In addition, we describe an optimized method for ISH analyses formiRNA detection in prostate tissues using locked nucleic acid (LNA)- based probes. Our optimized miRNA ISH protocol can be applied to prostate cancer tissue slides or prostate cancer tissue microarrays (TMA).

Here we describe a simplified protocol for microRNA (miRNA) expression analyses in archived Formalin-Fixed, Paraffin-Embedded (FFPE) or fresh frozen prostate cancer (PCa) clinical tissues employing quantitative real-time PCR (RT-PCR) and in situ hybridization (ISH).

A critical challenge in prostate cancer (PCa) clinical management is posed by the inadequacy of currently used biomarkers for disease screening, ...

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

Patient derived xenograft (PDX) models are gaining popularity in cancer research and are used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. Circulating tumor cells (CTC) play a critical role in tumor metastasis and have been isolated from patients with several tumor types. Recently, CTCs have been used to generate PDX experimental models of breast and prostate cancer. This manuscript details the method for the generation of prostate cancer PDX models from CTCs developed by our group. Advantages of this method over conventional PDX models include independence from surgical sample collection and generating experimental models at various disease stages. Density gradient centrifugation followed by red blood cell lysis and flow cytometry depletion of CD45 positive mononuclear cells is used to enrich CTCs from peripheral blood samples collected from patients with metastatic disease. The CTCs are then injected into immunocompromised mice; subsequently generated xenografts can be used for functional studies or harvested for molecular characterization. The primary limitation of this method is the negative selection method used for CTC enrichment. Despite this limitation, the generation of PDX models from CTCs provides a novel experimental model to be applied to prostate cancer research.

This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.

Patient derived xenograft (PDX) models are gaining popularity in cancer research and are used for preclinical drug evaluation, biomarker identification, ...

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

In this article, we describe a detailed protocol for miRNA detection in breast cancer tissue using in situ hybridization with a digoxigenin-labelled LNA (Locked Nucleic Acid) probe. The probe was recognized by anti-DIG alkaline phosphatase antibodies and later developed using alkaline phosphatase substrate producing fluorescence signals. Here we utilized miRNA in situ hybridization (MISH) technique to analyze expression of miR-489 in tissues from breast cancer patients. This technique can detect the localization of miRNA of interest in individual tissue samples. This technique can be used to compare the expression of desired miRNA in tumor tissue with that in adjacent normal tissue and to identify the specific structures responsible for expressing this miRNA. This technique can be very useful in answering certain clinical questions, such as role of specific miRNA in the development of cancer. Our results indicate that mammary epithelial cells express significantly higher levels of miR-489 than adjacent tumor cells.

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Here we present a protocol to detect miRNA expression in breast cancer patient samples using miRNA in situ hybridization.

In this article, we describe a detailed protocol for miRNA detection in breast cancer tissue using in situ hybridization with a digoxigenin-labelled LNA ...

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

To study the multifaceted biology of prostate cancer, pre-clinical in vivo models offer a range of options to uncover critical biological information about this disease. The human orthotopic prostate cancer xenograft mouse model provides a useful alternative approach for understanding the specific interactions between genetically and molecularly altered tumor cells, their organ microenvironment, and for evaluation of efficacy of therapeutic regimens. This is a well characterized model designed to study the molecular events of primary tumor development and it recapitulates the early events in the metastatic cascade prior to embolism and entry of tumor cells into the circulation. Thus it allows elucidation of molecular mechanisms underlying the initial phase of metastatic disease. In addition, this model can annotate drug targets of clinical relevance and is a valuable tool to study prostate cancer progression. In this manuscript we describe a detailed procedure to establish a human orthotopic prostate cancer xenograft mouse model.

Prostate cancer is the second most common cause of cancer-related deaths in the United States. An orthotopic cancer model provides a useful approach to understand the biology of prostate cancer and to evaluate the efficacy of therapeutic regimens. This protocol describes detailed steps necessary to establish an orthotopic prostate cancer mouse model.

To study the multifaceted biology of prostate cancer, pre-clinical in vivo models offer a range of options to uncover critical biological information ...

Speed

Subtitles

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer